Clinical Impact of the Time in Therapeutic Range on Early Hospital Readmission in Patients with Acute Heart Failure Treated with Oral Anticoagulation in Internal Medicine

<i>Background and objectives:</i> Patients with heart failure (HF) often present with non-valvular atrial fibrillation and require oral anticoagulation with coumarin anticoagulants such as acenocoumarol. The objective of this study was to evaluate the relationship between time in therape...

Full description

Bibliographic Details
Main Authors: Rubén Ángel Martín-Sánchez, Noel Lorenzo-Villalba, Alberto Elpidio Calvo-Elías, Ester Emilia Dubón-Peralta, Cynthia Elisa Chocrón-Benbunan, Carmen María Cano-de Luque, Lidia López-García, María Rivas-Molinero, Cristina Outón-González, Javier Marco-Martínez, Elpidio Calvo-Manuel, Emmanuel Andres, Manuel Méndez-Bailón
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Medicina
Subjects:
Online Access:https://www.mdpi.com/1648-9144/57/4/365
id doaj-2f613c23d45442b9abe3b41c815d155a
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Rubén Ángel Martín-Sánchez
Noel Lorenzo-Villalba
Alberto Elpidio Calvo-Elías
Ester Emilia Dubón-Peralta
Cynthia Elisa Chocrón-Benbunan
Carmen María Cano-de Luque
Lidia López-García
María Rivas-Molinero
Cristina Outón-González
Javier Marco-Martínez
Elpidio Calvo-Manuel
Emmanuel Andres
Manuel Méndez-Bailón
spellingShingle Rubén Ángel Martín-Sánchez
Noel Lorenzo-Villalba
Alberto Elpidio Calvo-Elías
Ester Emilia Dubón-Peralta
Cynthia Elisa Chocrón-Benbunan
Carmen María Cano-de Luque
Lidia López-García
María Rivas-Molinero
Cristina Outón-González
Javier Marco-Martínez
Elpidio Calvo-Manuel
Emmanuel Andres
Manuel Méndez-Bailón
Clinical Impact of the Time in Therapeutic Range on Early Hospital Readmission in Patients with Acute Heart Failure Treated with Oral Anticoagulation in Internal Medicine
Medicina
heart failure
non-valvular atrial fibrillation
acenocoumarol
time in therapeutic range
readmission
author_facet Rubén Ángel Martín-Sánchez
Noel Lorenzo-Villalba
Alberto Elpidio Calvo-Elías
Ester Emilia Dubón-Peralta
Cynthia Elisa Chocrón-Benbunan
Carmen María Cano-de Luque
Lidia López-García
María Rivas-Molinero
Cristina Outón-González
Javier Marco-Martínez
Elpidio Calvo-Manuel
Emmanuel Andres
Manuel Méndez-Bailón
author_sort Rubén Ángel Martín-Sánchez
title Clinical Impact of the Time in Therapeutic Range on Early Hospital Readmission in Patients with Acute Heart Failure Treated with Oral Anticoagulation in Internal Medicine
title_short Clinical Impact of the Time in Therapeutic Range on Early Hospital Readmission in Patients with Acute Heart Failure Treated with Oral Anticoagulation in Internal Medicine
title_full Clinical Impact of the Time in Therapeutic Range on Early Hospital Readmission in Patients with Acute Heart Failure Treated with Oral Anticoagulation in Internal Medicine
title_fullStr Clinical Impact of the Time in Therapeutic Range on Early Hospital Readmission in Patients with Acute Heart Failure Treated with Oral Anticoagulation in Internal Medicine
title_full_unstemmed Clinical Impact of the Time in Therapeutic Range on Early Hospital Readmission in Patients with Acute Heart Failure Treated with Oral Anticoagulation in Internal Medicine
title_sort clinical impact of the time in therapeutic range on early hospital readmission in patients with acute heart failure treated with oral anticoagulation in internal medicine
publisher MDPI AG
series Medicina
issn 1010-660X
1648-9144
publishDate 2021-04-01
description <i>Background and objectives:</i> Patients with heart failure (HF) often present with non-valvular atrial fibrillation and require oral anticoagulation with coumarin anticoagulants such as acenocoumarol. The objective of this study was to evaluate the relationship between time in therapeutic range (TTR) and the risk of early readmission. <i>Materials and Methods:</i> A retrospective descriptive study was carried out on hospitalized patients with a diagnosis of HF between 2014 and 2018 who had adverse effects due to oral anticoagulation with acenocoumarol (underdosing, overdosing, or hemorrhage). Clinical, analytical, therapeutic, and prognostic variables were collected. TTR is defined as the duration of time in which the patient’s International Normalized Ratio (INR) values were within a desired range. Early readmission was defined as readmission within 30 days after hospital discharge. Patients were divided into two groups depending on whether or not they had a TTR less than 60% (TTR < 60%) over the 6 months prior to the adverse event. <i>Results:</i> In the cohort of 304 patients, the mean age was 82 years, 59.9% of the patients were female, and 54.6% had a TTR < 60%. Patients with TTR < 60% had a higher HAS-BLED score (4.04 vs. 2.59; <i>p</i> < 0.001) and INR (6 vs. 5.31; <i>p</i> < 0.05) but lower hemoglobin (11.67 vs. 12.22 g/dL; <i>p</i> < 0.05). TTR < 60% was associated with early readmission after multivariate analysis (OR: 2.05 (CI 95%: 1.16–3.61)). They also had a higher percentage of hemorrhagic events and in-hospital mortality but without reaching statistical significance. <i>Conclusions:</i> Patients with HF and adverse events due to acenocoumarol often have poor INR control, which is independently associated with a higher risk of early readmission.
topic heart failure
non-valvular atrial fibrillation
acenocoumarol
time in therapeutic range
readmission
url https://www.mdpi.com/1648-9144/57/4/365
work_keys_str_mv AT rubenangelmartinsanchez clinicalimpactofthetimeintherapeuticrangeonearlyhospitalreadmissioninpatientswithacuteheartfailuretreatedwithoralanticoagulationininternalmedicine
AT noellorenzovillalba clinicalimpactofthetimeintherapeuticrangeonearlyhospitalreadmissioninpatientswithacuteheartfailuretreatedwithoralanticoagulationininternalmedicine
AT albertoelpidiocalvoelias clinicalimpactofthetimeintherapeuticrangeonearlyhospitalreadmissioninpatientswithacuteheartfailuretreatedwithoralanticoagulationininternalmedicine
AT esteremiliadubonperalta clinicalimpactofthetimeintherapeuticrangeonearlyhospitalreadmissioninpatientswithacuteheartfailuretreatedwithoralanticoagulationininternalmedicine
AT cynthiaelisachocronbenbunan clinicalimpactofthetimeintherapeuticrangeonearlyhospitalreadmissioninpatientswithacuteheartfailuretreatedwithoralanticoagulationininternalmedicine
AT carmenmariacanodeluque clinicalimpactofthetimeintherapeuticrangeonearlyhospitalreadmissioninpatientswithacuteheartfailuretreatedwithoralanticoagulationininternalmedicine
AT lidialopezgarcia clinicalimpactofthetimeintherapeuticrangeonearlyhospitalreadmissioninpatientswithacuteheartfailuretreatedwithoralanticoagulationininternalmedicine
AT mariarivasmolinero clinicalimpactofthetimeintherapeuticrangeonearlyhospitalreadmissioninpatientswithacuteheartfailuretreatedwithoralanticoagulationininternalmedicine
AT cristinaoutongonzalez clinicalimpactofthetimeintherapeuticrangeonearlyhospitalreadmissioninpatientswithacuteheartfailuretreatedwithoralanticoagulationininternalmedicine
AT javiermarcomartinez clinicalimpactofthetimeintherapeuticrangeonearlyhospitalreadmissioninpatientswithacuteheartfailuretreatedwithoralanticoagulationininternalmedicine
AT elpidiocalvomanuel clinicalimpactofthetimeintherapeuticrangeonearlyhospitalreadmissioninpatientswithacuteheartfailuretreatedwithoralanticoagulationininternalmedicine
AT emmanuelandres clinicalimpactofthetimeintherapeuticrangeonearlyhospitalreadmissioninpatientswithacuteheartfailuretreatedwithoralanticoagulationininternalmedicine
AT manuelmendezbailon clinicalimpactofthetimeintherapeuticrangeonearlyhospitalreadmissioninpatientswithacuteheartfailuretreatedwithoralanticoagulationininternalmedicine
_version_ 1721532276243693568
spelling doaj-2f613c23d45442b9abe3b41c815d155a2021-04-09T23:01:36ZengMDPI AGMedicina1010-660X1648-91442021-04-015736536510.3390/medicina57040365Clinical Impact of the Time in Therapeutic Range on Early Hospital Readmission in Patients with Acute Heart Failure Treated with Oral Anticoagulation in Internal MedicineRubén Ángel Martín-Sánchez0Noel Lorenzo-Villalba1Alberto Elpidio Calvo-Elías2Ester Emilia Dubón-Peralta3Cynthia Elisa Chocrón-Benbunan4Carmen María Cano-de Luque5Lidia López-García6María Rivas-Molinero7Cristina Outón-González8Javier Marco-Martínez9Elpidio Calvo-Manuel10Emmanuel Andres11Manuel Méndez-Bailón12Internal Medicine Department, Hospital Universitario Clínico San Carlos, Departamento de Medicina Universidad Complutense, Insituto de Investigacion Hospital Clinico San Carlos, 28040 Madrid, SpainService de Médecine Interne, Diabète et Maladies Métaboliques, Hôpitaux Universitaires de Strasbourg, 1 Place de l’Hôpital, 67000 Strasbourg, FranceInternal Medicine Department, Hospital Universitario Clínico San Carlos, Departamento de Medicina Universidad Complutense, Insituto de Investigacion Hospital Clinico San Carlos, 28040 Madrid, SpainInternal Medicine Department, Hospital Universitario Clínico San Carlos, Departamento de Medicina Universidad Complutense, Insituto de Investigacion Hospital Clinico San Carlos, 28040 Madrid, SpainInternal Medicine Department, Hospital Universitario Clínico San Carlos, Departamento de Medicina Universidad Complutense, Insituto de Investigacion Hospital Clinico San Carlos, 28040 Madrid, SpainInternal Medicine Department, Hospital Universitario Clínico San Carlos, Departamento de Medicina Universidad Complutense, Insituto de Investigacion Hospital Clinico San Carlos, 28040 Madrid, SpainInternal Medicine Department, Hospital Universitario Clínico San Carlos, Departamento de Medicina Universidad Complutense, Insituto de Investigacion Hospital Clinico San Carlos, 28040 Madrid, SpainInternal Medicine Department, Hospital Universitario Clínico San Carlos, Departamento de Medicina Universidad Complutense, Insituto de Investigacion Hospital Clinico San Carlos, 28040 Madrid, SpainInternal Medicine Department, Hospital Universitario Clínico San Carlos, Departamento de Medicina Universidad Complutense, Insituto de Investigacion Hospital Clinico San Carlos, 28040 Madrid, SpainInternal Medicine Department, Hospital Universitario Clínico San Carlos, Departamento de Medicina Universidad Complutense, Insituto de Investigacion Hospital Clinico San Carlos, 28040 Madrid, SpainInternal Medicine Department, Hospital Universitario Clínico San Carlos, Departamento de Medicina Universidad Complutense, Insituto de Investigacion Hospital Clinico San Carlos, 28040 Madrid, SpainService de Médecine Interne, Diabète et Maladies Métaboliques, Hôpitaux Universitaires de Strasbourg, 1 Place de l’Hôpital, 67000 Strasbourg, FranceInternal Medicine Department, Hospital Universitario Clínico San Carlos, Departamento de Medicina Universidad Complutense, Insituto de Investigacion Hospital Clinico San Carlos, 28040 Madrid, Spain<i>Background and objectives:</i> Patients with heart failure (HF) often present with non-valvular atrial fibrillation and require oral anticoagulation with coumarin anticoagulants such as acenocoumarol. The objective of this study was to evaluate the relationship between time in therapeutic range (TTR) and the risk of early readmission. <i>Materials and Methods:</i> A retrospective descriptive study was carried out on hospitalized patients with a diagnosis of HF between 2014 and 2018 who had adverse effects due to oral anticoagulation with acenocoumarol (underdosing, overdosing, or hemorrhage). Clinical, analytical, therapeutic, and prognostic variables were collected. TTR is defined as the duration of time in which the patient’s International Normalized Ratio (INR) values were within a desired range. Early readmission was defined as readmission within 30 days after hospital discharge. Patients were divided into two groups depending on whether or not they had a TTR less than 60% (TTR < 60%) over the 6 months prior to the adverse event. <i>Results:</i> In the cohort of 304 patients, the mean age was 82 years, 59.9% of the patients were female, and 54.6% had a TTR < 60%. Patients with TTR < 60% had a higher HAS-BLED score (4.04 vs. 2.59; <i>p</i> < 0.001) and INR (6 vs. 5.31; <i>p</i> < 0.05) but lower hemoglobin (11.67 vs. 12.22 g/dL; <i>p</i> < 0.05). TTR < 60% was associated with early readmission after multivariate analysis (OR: 2.05 (CI 95%: 1.16–3.61)). They also had a higher percentage of hemorrhagic events and in-hospital mortality but without reaching statistical significance. <i>Conclusions:</i> Patients with HF and adverse events due to acenocoumarol often have poor INR control, which is independently associated with a higher risk of early readmission.https://www.mdpi.com/1648-9144/57/4/365heart failurenon-valvular atrial fibrillationacenocoumaroltime in therapeutic rangereadmission